Bajaj Healthcare reported a strong Q1 FY27 with revenue rising 11.3% to ₹165.63 crore and net profit increasing 15.8% to ₹13.7 crore. The domestic API segment was a key growth driver, offsetting a dip in exports. The company also achieved a regulatory milestone with SEC recommendation for a new anti-seizure medication.
Bajaj Healthcare Q1 FY27 Earnings
Revenue from operations ₹165.63 Cr; Net Profit ₹13.7 Cr
Reader Takeaway: Domestic API strength drives double-digit growth, while exports face temporary headwinds.
What just happened
Bajaj Healthcare Ltd. announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a 11.3% year-on-year increase in revenue from operations, reaching ₹165.63 crore. Net profit saw a significant rise of 15.8%, amounting to ₹13.7 crore. EBITDA grew by 16.4% to ₹29.56 crore, and gross profit increased by 16.2% to ₹80.35 crore.
Why this matters
The results indicate a positive growth trajectory for Bajaj Healthcare, driven by strong performance in its domestic Active Pharmaceutical Ingredient (API) segment. Improved margins, with gross margin expanding to 48.3% and EBITDA margin to 17.8%, suggest enhanced operational efficiency and a favourable product mix. The company also secured a significant regulatory milestone with an SEC recommendation for manufacturing a new anti-seizure medication, Cenobamate Tablets, and expanded its R&D capabilities.
The backstory
In the previous fiscal year (FY26), Bajaj Healthcare had shown steady performance, focusing on expanding its product portfolio and market reach. The company has been investing in R&D and regulatory filings to strengthen its long-term competitive position.
What changes now
With the operationalization of its expanded R&D center and the SEC recommendation for Cenobamate Tablets, Bajaj Healthcare is poised to enhance its product development pipeline and potentially capture new market opportunities. The company's focus on operational discipline and product mix is expected to sustain profitability.
Risks to watch
While the domestic API segment is performing well, the company's API exports faced a decline of 4.1% due to geopolitical issues in West Asia. The formulations segment also saw a slight dip. Investors will be watching how the company navigates these external challenges and achieves expected normalization in the formulations business.
Peer comparison
While specific peer comparisons are not detailed in the filing, the sector typically sees competition based on product innovation, regulatory approvals, and manufacturing efficiency. Bajaj Healthcare's focus on R&D and securing regulatory milestones positions it competitively.
Context metrics (time-bound)
- Revenue from Operations: ₹165.63 Cr in Q1 FY27, up from ₹148.84 Cr in Q1 FY26.
- Net Profit (PAT): ₹13.70 Cr in Q1 FY27, up from ₹11.83 Cr in Q1 FY26.
- EBITDA: ₹29.56 Cr in Q1 FY27, up from ₹25.39 Cr in Q1 FY26.
- Gross Margin: 48.3% in Q1 FY27, up from 46.2% in Q1 FY26.
- EBITDA Margin: 17.8% in Q1 FY27, up from 17.0% in Q1 FY26.
What to track next
Investors should monitor the progress of the API Exports and Formulations segments towards expected normalization. The commercialization timeline for Cenobamate Tablets and the success of new CEP applications will also be key areas to track.